Plasmapheresis and antiplatelet agents in the treatment of the hemolytic uremic syndrome secondary to mitomycin.
Four patients with the hemolytic uremic syndrome secondary to mitomycin therapy were treated with intense plasmapheresis and antiplatelet agents. All four patients had a hematologic response and three had slow, but steady, improvement in renal function. These results suggest an important role for these agents in mitomycin-induced hemolytic uremic syndrome.
D000230:Adenocarcinoma / Q000188:drug therapy; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001120:Arginine / Q000031:analogs & derivatives*; D001125:Argininosuccinic Acid / Q000008:administration & dosage*; D001792:Blood Platelets / Q000187:drug effects*; D001943:Breast Neoplasms / Q000188:drug therapy; D003404:Creatinine / Q000097:blood; D004176:Dipyridamole / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008875:Middle Aged; D016685:Mitomycin; D008937:Mitomycins / Q000009:adverse effects*; D010956:Plasmapheresis; D013442:Sulfinpyrazone / Q000627:therapeutic use*; D013608:Tablets, Enteric-Coated; D013997:Time Factors
D008937:Mitomycins; D013608:Tablets, Enteric-Coated; D001125:Argininosuccinic Acid; D016685:Mitomycin; D004176:Dipyridamole; D001120:Arginine; D003404:Creatinine; D013442:Sulfinpyrazone